Bank Pictet & Cie Europe AG Purchases 136,605 Shares of Gilead Sciences, Inc. $GILD

Bank Pictet & Cie Europe AG raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 893.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,893 shares of the biopharmaceutical company’s stock after buying an additional 136,605 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Gilead Sciences were worth $18,643,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in GILD. Brighton Jones LLC raised its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences during the 4th quarter worth $215,000. Sivia Capital Partners LLC raised its holdings in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Gilead Sciences by 54.0% in the 2nd quarter. Fisher Asset Management LLC now owns 10,700 shares of the biopharmaceutical company’s stock valued at $1,186,000 after acquiring an additional 3,750 shares in the last quarter. Finally, Westerkirk Capital Inc. bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $622,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the chief financial officer owned 179,191 shares of the company’s stock, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 299,280 shares of company stock valued at $42,820,550. Company insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on GILD shares. HSBC increased their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Barclays began coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective on the stock. Leerink Partners raised their target price on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Finally, Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $140.30 on Thursday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The stock has a market capitalization of $174.14 billion, a P/E ratio of 20.72, a price-to-earnings-growth ratio of 1.83 and a beta of 0.37. The stock has a fifty day moving average of $144.85 and a 200-day moving average of $129.14.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same period last year, the firm posted $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is 48.45%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Ouro Medicines and struck a binding collaboration with Galapagos to advance T‑cell engager programs for autoimmune diseases — a clear push to expand its pipeline into potentially high‑value biologics and diversify beyond core antiviral franchises, which supports longer‑term growth expectations. Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
• Positive Sentiment: RBC noted decent patient persistence for Yeztugo (HIV prevention), indicating commercial uptake is intact even if market expansion is limited — positive for ongoing revenue stability from Gilead’s HIV portfolio. Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says
• Neutral Sentiment: Analysts expect single‑digit EPS growth for Q1 2026 — modest growth that keeps expectations muted vs. high‑growth peers but aligns with Gilead’s guidance and stable cash generation. This sets tempered near‑term performance expectations. Gilead Sciences’s Q1 2026 Earnings: What to Expect
• Neutral Sentiment: Market roundups and earnings/transcript coverage show Gilead’s stock has risen in recent sessions but still lagged broader indices — reflecting investor caution despite positive headlines. These pieces mainly summarize momentum rather than introduce new catalysts. Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
• Neutral Sentiment: General investor commentary listing Gilead as an attractive dividend/ income name may support demand from income investors but is not an immediate catalyst for a large re‑rating. Markets Haven’t Changed. These 2 Cheap Dividends Still Rule
• Negative Sentiment: Gilead extended the tender offer for Arcellx at $115 plus a $5 CVR — the extension signals the deal hasn’t closed and increases short‑term uncertainty (and potential near‑term cash outflow). Investors may view extensions as a risk that the acquisition will be more costly, contested, or delayed. Gilead Extends Tender Offer to Acquire Arcellx

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.